As the Pfizer-Allergan merger talks heat up, shining yet another spotlight on the tax inversion issue, a Goldman Sachs report notes that it is up to the U.S. Treasury and IRS to stem flood of corporations fleeing the U.S. tax system for more friendly climates abroad.

Pfizer / Allergan acquisition would result in a tax inversion, as clock is ticking
If drug giant Pfizer Inc. is successful in . . .

SORRY!

This content is exclusively for paying members. Access all of our content on including years of timeless investment news and in depth analysis for only a few dollars a month by signing up here while also supporting quality content and journalism, or learn more about our premium content here

If you are subscribed and having an account error please clear cache and then cookies if that does not work email support@valuewalk.com and we will get back to you as quick as humanly possible